Breast Cancer

In this episode, VTE rate with abemaciclib higher in real-world setting; Enhertu extends progression-free survival in patient subgroup; FDA grants priority review to elacestrant for metastatic disease; and more.

Maryam Lustberg, MD, MPH, has made it a priority to support patients and their families, give back through mentoring and normalize struggles women oncologists face.

Medicaid-insured women diagnosed with primary hormone receptor-positive breast cancer had lower odds of short- and long-term adherence to adjuvant endocrine therapy if they had a longer time to initiation of the therapy.

Background parenchymal enhancement at surveillance breast MRI appeared independently associated with future second breast cancer risk among women with a personal history of breast cancer, according to study results published in Radiology.

One-third of a cohort of young breast cancer survivors experienced significant weight gain at 3 years after diagnosis, according to study results.

Submitted medical claims and out-of-pocket costs for genetic counseling encounters appeared relatively low among patients with certain cancer types, according to a research letter published in JAMA Health Forum.

Fewer than half of breast cancer studies in the National Cancer Database reported Hispanic ethnicity and about one-third categorized race and ethnicity into mutually exclusive groups, according to study results.

Individuals who increased alcohol consumption had higher risks for both alcohol-associated and all cancer types, according to results of a Korean population-based cohort study published in JAMA Network Open.

The FDA granted priority review to elacestrant for ER-positive, HER2-negative advanced or metastatic breast cancer.

Although the number of Americans insured through Medicaid has increased during the past decade, barriers to cancer care access exist among Medicaid beneficiaries across high-quality centers, according to study results in JAMA Network Open.